Accuracy, feasibility, and clinical impact of prospective bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy

Clinical Cancer Research

Volumn 11, Issue 1, 2005, Pages 273-283

  De Jonge, Milly E ^a   Huitema, Alwin D R ^a   Tukker, Annemarie C ^b   Van Dam, Selma M ^a   Rodenhuis, Sjoerd ^b   Beijnen, Jos H ^a,b  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; CARBOPLATIN; CYCLOPHOSPHAMIDE; TEPA; THIOTEPA;

ADULT; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; DRUG MONITORING; FEMALE; GERM CELL TUMOR; HUMAN; MALE; PRIORITY JOURNAL; VEIN OCCLUSION;

ADOLESCENT; ADULT; ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BAYES THEOREM; BREAST NEOPLASMS; CARBOPLATIN; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEOPLASMS, GERM CELL AND EMBRYONAL; OVARIAN NEOPLASMS; THIOTEPA; TIME FACTORS; TREATMENT OUTCOME;

EID: 11344256440     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Van Der Wall E, Beijnen JH, Rodenhuis S. High-dose chemotherapy regimens for solid tumors. Cancer Treat Rev 1995;21:105-32.
2. Rodenhuis S, Bontenbal M, Beex LV, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 2003;349:7-16.
3. Rodenhuis S, Richel DJ, Van Der Wall E, et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 1998;352:515-21.
4. Rodenhuis S, Westerman A, Holtkamp MJ, et al. Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer. J Clin Oncol 1996;14:1473-83.
5. Rodenhuis S, De Wit R, De Mulder PHM, et al. A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission. Ann Oncol 1999;10:1467-73.
6. Schrama JG, Baars JW, Holtkamp MJ, Schornagel JH, Beijnen JH, Rodenhuis S. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer. Bone Marrow Transplant 2001;28:173-80.
7. De Jonge ME, Huitema ADR, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet. In press.
8. Van Maanen MJ, Smeets CJ, Beijnen JH. Chemistry, pharmacology and pharmacokinetics of N,N′,N-triethylenethiophosphoramide (ThioTEPA). Cancer Treat Rev 2000;26:257-68.
9. Jacobson PA, Green K, Birnbaum A, Remmel RP. Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to tepa. Cancer Chemother Pharmacol 2002;49:461-7.
10. Chang TKH, Chen G, Waxman DJ. Modulation of thioTEPA anti-tumor activity in-vivo by alteration of liver cytochrome P450-catalyzed drug-metabolism. J Pharmacol Exp Ther 1995;274:270-5.
11. Teicher BA, Waxman DJ, Holden SA, et al. Evidence for enzymatic activation and oxygen involvement in cytotoxicity and anti-tumor activity of N,N′,N-triethylenethiophosphoramide. Cancer Res 1989;49:4996-5001.
12. Miller B, Tenenholz T, Egorin MJ, Sosnovsky G, Rao NU, Gutierrez PL. Cellular pharmacology of N,N′,N-triethylenethiophosphoramide. Cancer Lett 1988;41:157-68.
13. De Jonge ME, Huitema ADR, Rodenhuis S, Beijnen JH. Integrated population pharmacokinetic model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction. J Pharmacokinet Pharmacodyn 2004;31:135-56.
14. Van Der Vijgh WJM. Clinical Pharmacokinetics of carboplatin. Clin Pharmacokinet 1991;21:242-61.
15. Huitema ADR, Spaander M, Mathôt RAA, et al. Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thioTEPA and carboplatin. Ann Oncol 2002;13:374-84.
16. Schrama JG, Holtkamp MJ, Baars JW, Schornagel JH, Rodenhuis S. Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience. Br J Cancer 2003;88:1831-8.
17. Ayash LJ, Wright JE, Tretyakov O, et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 1992;10:995-1000.
18. Petros WP, Broadwater G, Berry D, et al. Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. Clin Cancer Res 2002;8:698-705.
19. Przepiorka D, Madden T, Ippoliti C, Estrov Z, Dimopoulos M. Dosing of thiotepa for myeloablative therapy. Cancer Chemother Pharmacol 1995;37:155-60.
20. Eder JP, Antman K, Elias A, et at. Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors. J Natl Cancer Inst 1988;80:1221-6.
21. Hussein AM, Petros WP, Ross M, et al. A phase I/II study of high-dose cyclophosphamide, cisplatin, and thiotepa followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral blood progenitor cells in patients with advanced malignancies. Cancer Chemother Pharmacol 1996;37:561-8.
22. Van Warmerdam LJC, Rodenhuis S, Van Der Wall E, Maes RAA, Beijnen JH. Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support. Br J Cancer 1996;73:979-84.
23. Shea TC, Flaherty M, Elias A, et al. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 1989;7:651-61.
24. Wright JE, Elias A, Tretyakov O, et al. High-dose ifosfamide, carboplatin, and etoposide pharmacokinetics: correlation of plasma drug levels with renal toxicity. Cancer Chemother Pharmacol 1995;36:345-51.
25. Colby C, Koziol S, McAfee SL, Yeap B, Spitzer TR. High-dose carboplatin and regimen-related toxicity following autologous bone marrow transplant. Bone Marrow Transplant 2002;26:467-72.
26. Kloft C, Siegert W, Beyer J, Jaehde U. Toxicity of high-dose carboplatin: ultrafiltered and not total plasma pharmacokinetics is of clinical relevance. J Clin Pharmacol 2002;42:762-73.
27. Huitema ADR, Mathôt RAA, Tibben MM, Schellens JHM, Rodenhuis S, Beijnen JH. Population pharmacokinetics of thiotepa and its active metabolite tepa in high-dose chemotherapy. Br J Clin Pharmacol 2001;51:61-70.
28. Huitema ADR, Mathôt RAA, Tibben MM, Schellens JH, Rodenhuis S, Beijnen JH. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods. Clin Pharmacol Ther 2000;67:621-30.
29. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56.
30. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
31. De Jonge ME, Van Dam SM, Hillebrand MJX, et al. Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N′,N-triethylenethiophosphoramide (thiotepa) and N,N′,N- triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS-MS). J Mass Spectrom 2004;39:262-71.
32. Van Warmerdam LJC, Van Tellingen O, Maes RAA, Beijnen JH. Validated method for the determination of carboplatin in biological fluids by Zeeman atomic absorption spectrometry. Fresenius J Anal Chem 1995;352:777-81.
33. Huitema ADR, Tibben MM, Kerbusch T, Zwikker JW, Rodenhuis S, Beijnen JH. Simultaneous determination of N,N'′,N-triethylenethiophosphoramide, cyclophosphamide and some of their metabolites in plasma using capillary gas chromatography. J Chromatogr B Biomed Sci Appl 1998;716:177-86.
34. Beal SL, Sheiner LB. NONMEM user's guides. NONMEM Project Group. San Francisco: University of California at San Francisco; 1998.
35. Division of Cancer Treatment, National Cancer Institute. Guidelines for reporting of adverse drug reactions. Bethesda (MD): Division of Cancer Treatment, National Cancer Institute; 1998.
36. Peng B, Boddy AV, Cole M, et al. Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients. Eur J Cancer 1995;31A:1804-10.
37. Ren S, Kalhorn TF, McDonald GB, Anasetti C, Appelbaum FR, Slattery JT. Pharmacokinetics of cyclophosphamide and its metabolites in bone-marrow transplantation patients. Clin Pharmacol Ther 1998;64:289-301.
38. Sladek NE, Doeden D, Powers JF, Krivit W. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Cancer Treat Rep 1984;68:1247-54.
39. Busse D, Busch FW, Bohnenstengel F, et al. Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism. J Clin Oncol 1997;15:1885-96.
40. Chen TL, Kennedy MJ, Anderson LW, et al. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone-marrow transplantation. Drug Metab Dispos 1997;25:544-51.